Novo Nordisk and Akero Therapeutics announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed.

With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for US$ 54 per share in cash (or aggregated value of US$ 4.7 billion and a non-transferable Contingent Value Right (CVR).

Each CVR entitles its holder to an additional payment of $6 per share in cash (or aggregated value of $ 0.5 billion) upon US regulatory approval of Akero’s lead candidate EFX for the treatment of compensated cirrhosis due to MASH.

At the completion of the transaction, Akero became a wholly owned subsidiary of Novo Nordisk. The common stock of Akero will no longer be listed or traded on the Nasdaq Global Select Market.